.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
AFFIRM-AHF evaluated intravenous ferric carboxymaltose in patients hospitalized with acute heart failure who also had iron deficiency. Patients received treatment around the time of discharge and were followed for recurrent heart-failure hospitalizations and cardiovascular death. Although the primary composite outcome did not achieve conventional statistical significance for the combined endpoint, ferric carboxymaltose reduced recurrent heart-failure hospitalizations, supporting a clinically relevant effect on post-discharge morbidity. The study is important because iron deficiency is common in heart failure and may contribute to fatigue, reduced exercise capacity and poorer outcomes even when anemia is not severe. For internists, the practical issue is systematic identification of iron deficiency rather than assuming that hemoglobin alone captures the problem. Ferritin and transferrin saturation can help define patients who may benefit from replacement. Intravenous therapy can be particularly useful when rapid repletion is needed or oral absorption is limited. The broader message is that guideline-directed heart-failure care extends beyond conventional neurohormonal therapy: correcting important comorbid biologic deficits may reduce rehospitalization and improve functional status.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
AFFIRM-AHF evaluated intravenous ferric carboxymaltose in patients hospitalized with acute heart failure who also had iron deficiency. Patients received treatment around the time of discharge and were followed for recurrent heart-failure hospitalizations and cardiovascular death. Although the primary composite outcome did not achieve conventional statistical significance for the combined endpoint, ferric carboxymaltose reduced recurrent heart-failure hospitalizations, supporting a clinically relevant effect on post-discharge morbidity. The study is important because iron deficiency is common in heart failure and may contribute to fatigue, reduced exercise capacity and poorer outcomes even when anemia is not severe. For internists, the practical issue is systematic identification of iron deficiency rather than assuming that hemoglobin alone captures the problem. Ferritin and transferrin saturation can help define patients who may benefit from replacement. Intravenous therapy can be particularly useful when rapid repletion is needed or oral absorption is limited. The broader message is that guideline-directed heart-failure care extends beyond conventional neurohormonal therapy: correcting important comorbid biologic deficits may reduce rehospitalization and improve functional status.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
